429 results about "Virus vaccine" patented technology

The present invention provides a mobile communication system and method for inactivating or curing mobile communication viruses. The mobile communication system for inactivating a virus includes: a database associated with the mobile communication system, for storing at least one virus vaccine program; and a virus monitoring unit associated with the mobile communication system, for checking virus infection of received data, analyzing virus information, choosing one of virus vaccine programs that are stored in the database and inactivating the virus. Virus vaccine programs are timely updated over the air (OTA) whenever a new version of vaccine program is available.

The invention discloses a method for quickly preparing a vaccine by editing pseudorabies virus genomes based on a CRISPR / Cas9 gene editing system and a Cre / lox recombination system and an application of the method. According to the method, the CRISPR / Cas9 gene editing system is used for synchronously and efficiently recombining a GFP gene and a mCherry gene to a pseudorabies virus gE gene site and a TK gene site respectively to obtain conditional deletion strains of a gE gene and a TK gene; after purification, the Cre / lox system is used for cutting off extraneous GFP and mCherry genes in the pseudorabies virus recombinant virus genome so as to perform purification quickly to obtain a live pseudorabies virus vaccine lack of gE / TK genes; multiple genes are operated at the same time, so that multiple rounds of flows for knocking out multiple genes in the conventional method are reduced to one round; and meanwhile, the efficient edition of virus genes by using the CRISPR / Cas9 and Cre / lox systems simplifies about thirty generations of plaque purification processes into 3-4 generations, so that the preparation efficiency of the virus vaccine is greatly improved, and the method provides a strong guarantee for effectively preventing and controlling the larger-range popularization of variant pseudorabies viruses and reducing heavy economic losses.

The present invention provides a mobile communication system and method for inactivating or curing mobile communication viruses. The mobile communication system for inactivating a virus includes: a database associated with the mobile communication system, for storing at least one virus vaccine program; and a virus monitoring unit associated with the mobile communication system, for checking virus infection of received data, analyzing virus information, choosing one of virus vaccine programs that are stored in the database and inactivating the virus. Virus vaccine programs are timely updated over the air (OTA) whenever a new version of vaccine program is available.

Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.

The invention relates to fusion protein of SARS-Cov virus structural protein and its high expression and purification in mammalian cell and its usage. The construction of said fusion protein is X-Y-z, and X is S or M or E or N selected from SARS-CoV virus construction protein, or their arbitrary short form; Y is the connection part with 0-20 amino acid; Z is Fc and its modification or other protein tag. The invention also provides the method of expressing and purifying said fusion protein in mammalian cell for the batch preparation or industrial production. The fusion protein can be used to prepare genetic engineering vaccine preventing SARS-CoV virus infection, solvent box for checking SARS-CoV virus, and to sift drug anti SARS-CoV virus infection with S protein combined with its acceptor ACE2. The invention can detect combination of S protein of SARS-CoV virus with ACE2, which reduces ACE2 expression, and result in or exacerbate acute lung damage, then it modifies combined segment, which can improve safety of preventing SARS-CoV virus vaccine.

The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

The invention provides a recombinant duck virus enteritis virus vaccine strain CCTCC No.V201026, named as rDEVul41HA, for expressing avian influenza virus hemagglutinin (HA) genes and a construction method as well as application thereof. Specifically, gene segments SV40-HA containing avian influenza virus hemagglutinin HA genes and a SV40 promoter sequence are inserted into UL41 genes of duck virus enteritis virus to construct cosmids with SV40-HA expression cassette inserted into UL41 genes; and by the cosmids, the recombinant duck virus enteritis virus vaccine strain CCTCC V201026 for expressing the avian influenza virus hemagglutinin (HA) genes is saved and obtained. The invention also relates to a method for constructing the recombinant duck virus enteritis virus vaccine strain and application of the recombinant duck virus enteritis virus vaccine strain to preparing vaccines for preventing duck virus enteritis and avian influenza.

The invention relates to reconstructing LaSota weak poison vaccine strain to express wild type or mutant type fowl influenza virus H5 HA albumen. Concretely, it is rL-QHwH5 and rL-QHmH5. The invention also discloses the method to make the LaSota weak poison vaccine and the application in defending fowl influenza virus.

The utility model provides a method of bioreactor micro-carrier for cultivating human diploid cell to produce viral vaccine. The method comprises the following steps: reviving human diploid cell; amplifying the culture of the human diploid cell and preparing the cell suspension; inoculating the obtained cell suspension to the bioreactor, fresh complete cell growth culture solution for sterilizing and micro-carrier are pre-added into the micro-carrier, the final density of the inoculated cell is 5*104-2*106 cell / ml, the monolayer cell of the micro-carrier is cultivated under the conditions that the temperature is 35 to 39 degrees, pH is 6.5 to 8.0, and the dissolved oxygen is 15 to 100%, and the cell density amounts to more than 1*106 cell / ml; and inoculating, breeding and harvesting virus. According to the method, utilizing the bioreactor for cultivating the human diploid cell to produce the virus vaccine in large scale becomes possible, the produced virus vaccine has high output and consistency, and the large-scale industrial production for the virus vaccine is effectively realized.

The invention discloses a fusion protein comprising an Fc domain of IgG and an extracellular domain of an EB virus envelope glycoprotein. The fusion protein is represented by the following formula: P-E-F, wherein P represents a secretion signal peptide, E represents an amino acid sequence of the extracellular domain of the EB virus envelope glycoprotein gp350, and F represents the amino acid sequence of the Fc domain of the IgG. It is found for the first time that after the fusion of the Fc domain of the immunoglobulin IgG with the envelope glycoprotein gp350 from the surface of the EB virus,the immunogenicity in vivo is significantly improved. After immunization with the fusion protein, the total serum titer an immunized animal, the serum specific neutralizing antibody titer and the serum in vitro viral infection blocking efficiency are significantly higher than that of a non-fused control protein. The fusion protein using the Fc domain of the immunoglobulin IgG and the EB virus membrane glycoprotein is adopted as an evidence for the efficacy of an EB virus vaccine and has important practical and theoretical significance and application prospects for prevention and treatment of EB virus-related diseases.

The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

The invention relates to a heat-resisting lyophilized protector for a recombinant pseudorabies virus vaccine. The heat-resisting lyophilized protector comprises the following ingredients by weight: 2 to 3 percent of gelatin, 1 to 2 percent of polyvinylpyrrolidone K-30, 0 to 4 percent of trehalose, 2 to 5 percent of saccharose, 0.1 to 0.5 percent of mannitol, 0 to 0.5 percent of astragalus polysaccharide, 1 to 1.5 percent of glycine, 0 to 1 percent of arginine, 0 to 1 percent of bovine serum albumin and the balance of water for injection. The invention further provides a preparation method of the heat-resisting lyophilized protector. The heat-resisting lyophilized protector has the advantage that the preservation period of the vaccine in a relatively-high-temperature environment can be prolonged; the preparation method is simple; the production and the application are convenient.